ACM
BIB icon

Argentus Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Argentus Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,276
Closed -$62K – 28
2016
Q3 		$62K Hold
1,276
– – 0.02% 414
2016
Q2 		$50K Hold
1,276
– – 0.02% 441
2016
Q1 		$52K Hold
1,276
– – 0.02% 437
2015
Q4 		$91K Sell
1,276
-2,251
-64% -$150K 0.03% 353
2015
Q3 		$206K Buy
+3,527
New +$301K 0.03% 393

Other funds holding BIB

RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TH
Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Argentus Capital Management's BIB Position: Q4 2016 in Review

Argentus Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2016, closing a stake of 1,276 shares — an estimated $62K sold.

Argentus Capital Management first reported a position in BIB in Q3 2015 and held it in 5 quarters. The position peaked at $206K in Q3 2015. 31 funds tracked by Wall St. Rank hold BIB as of Q4 2016.

  • Argentus Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
  • Argentus Capital Management sold 1,276 ProShares Ultra NASDAQ Biotechnology shares in Q4 2016, an estimated $62K.
  • Argentus Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2015 and held it in 5 quarters.
  • Argentus Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $206K in Q3 2015.
  • 31 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2016.

Based on Argentus Capital Management's 13F filing for Q4 2016.